|
2025-06-16 |
2025-06-13 |
VP
Vente planifiée
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
1 000
-2.3%
28,43
51 909 USD
|
1 000
-2.3%
|
28,43
|
100 000 USD
|
|
|
2025-06-16 |
2025-06-13 |
VP
Vente planifiée
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
1 000
-15.0%
28,42
406 601 USD
|
1 000
-15.0%
|
28,42
|
100 000 USD
|
|
|
2025-06-16 |
2025-06-13 |
VP
Vente planifiée
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
1 000
-1.3%
28,47
35 669 USD
|
1 000
-1.3%
|
28,47
|
100 000 USD
|
|
|
2025-06-16 |
2025-06-13 |
VP
Vente planifiée
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
1 000
-8.3%
28,46
248 953 USD
|
1 000
-8.3%
|
28,46
|
100 000 USD
|
|
|
2025-05-27 |
2025-05-27 |
V
Vente
|
Holloway Jean F
SVP, General Counsel
Dirigeant
|
8 748
-4.7%
29,00
253 692 USD
|
8 748
-4.7%
|
29,00
|
253 692 USD
|
|
|
2025-05-27 |
2025-05-23 |
V
Vente
|
SEMEDO ANTHONY B.
Administrateur non-exécutif
|
2 600
-7.3%
28,47
74 027 USD
|
2 600
-7.3%
|
28,47
|
74 027 USD
|
|
|
2025-05-21 |
2025-05-21 |
V
Vente
|
Holloway Jean F
SVP, General Counsel
Dirigeant
|
9 926
-5.0%
29,00
287 854 USD
|
9 926
-5.0%
|
29,00
|
287 854 USD
|
|
|
2025-05-12 |
2025-05-09 |
V
Vente
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
4 811
-4.4%
29,13
140 145 USD
|
4 811
-4.4%
|
29,13
|
140 145 USD
|
|
|
2025-05-12 |
2025-05-09 |
V
Vente
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
5 737
-5.0%
29,13
167 120 USD
|
5 737
-5.0%
|
29,13
|
167 120 USD
|
|
|
2025-03-12 |
2025-03-11 |
VP
Vente planifiée
|
Holloway Jean F
SVP, General Counsel
Dirigeant
|
18 020
-8.4%
23,61
425 510 USD
|
18 020
-8.4%
|
23,61
|
425 510 USD
|
|
|
2025-03-12 |
2025-03-11 |
VP
Vente planifiée
|
Davis John E
Chief Commercial Officer
Dirigeant
|
15 100
-6.7%
23,61
356 549 USD
|
15 100
-6.7%
|
23,61
|
356 549 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Horton Amy
VP, Chief Accounting Officer
Dirigeant
|
1 048
-0.7%
24,80
25 995 USD
|
1 048
-0.7%
|
24,80
|
25 995 USD
|
|
|
2025-03-10 |
2025-03-06 |
VP
Vente planifiée
|
Mackin James P
President & CEO
Dirigeant
|
70 700
-7.6%
24,76
1 750 843 USD
|
70 700
-7.6%
|
24,76
|
1 750 843 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Mackin James P
President & CEO
Dirigeant
|
17 739
-2.0%
24,80
440 005 USD
|
17 739
-2.0%
|
24,80
|
440 005 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Holloway Jean F
SVP, General Counsel
Dirigeant
|
2 124
-1.1%
24,80
52 685 USD
|
2 124
-1.1%
|
24,80
|
52 685 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Davis John E
Chief Commercial Officer
Dirigeant
|
2 618
-1.2%
24,80
64 939 USD
|
2 618
-1.2%
|
24,80
|
64 939 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Stanton Marshall S.
SVP, Clinical & MD Affair
Dirigeant
|
1 603
-1.4%
24,80
39 761 USD
|
1 603
-1.4%
|
24,80
|
39 761 USD
|
|
|
2025-03-10 |
2025-03-06 |
V
Vente
|
Berry Lance A
Executive VP, CFO
Dirigeant
|
4 909
-3.1%
24,80
121 764 USD
|
4 909
-3.1%
|
24,80
|
121 764 USD
|
|
|
2025-03-06 |
2025-03-05 |
V
Vente
|
Holloway Jean F
SVP, General Counsel
Dirigeant
|
472
-0.3%
25,29
11 935 USD
|
472
-0.3%
|
25,29
|
11 935 USD
|
|
|
2025-03-05 |
2025-03-05 |
A
Achat
|
SEMEDO ANTHONY B.
Administrateur non-exécutif
|
600
+inf%
25,25
15 150 USD
|
600
+inf%
|
25,25
|
15 150 USD
|
|
